AOT 2026 | Professor Donal P. McLornan: Challenges, Strategies, and Future Directions for Hematopoietic Stem Cell Transplantation in MDS/MPN

AOT 2026 | Professor Donal P. McLornan: Challenges, Strategies, and Future Directions for Hematopoietic Stem Cell Transplantation in MDS/MPN

To comprehensively improve public health and strengthen strategies for the prevention and treatment of major diseases, medical innovation and international collaboration have become key drivers of clinical progress. Against this backdrop, the 2026 Beijing International Hematopoietic Stem Cell Transplantation Conference (AOT) was successfully held in Beijing from April 24 to 25, 2026. Organized by the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care and hosted by the National Clinical Research Center for Hematologic Diseases and the Peking University Institute of Hematology, this year’s conference centered on the theme “The Art of Transplantation.” The meeting brought together leading hematology experts from around the world to discuss cutting-edge innovations and emerging trends in hematopoietic stem cell transplantation.
CSCO Guideline Preview | Professor Cuijian Zhang: Six Years of Evolution in the Urothelial Carcinoma Guidelines as ADCs and Novel Therapies Further Reshape Clinical Practice

CSCO Guideline Preview | Professor Cuijian Zhang: Six Years of Evolution in the Urothelial Carcinoma Guidelines as ADCs and Novel Therapies Further Reshape Clinical Practice

With the continuous emergence of novel therapies and landmark clinical evidence, the treatment landscape of urothelial carcinoma is undergoing profound transformation. Ahead of the 2026 Chinese Society of Clinical Oncology (CSCO) Guidelines Conference, Oncology Frontier – UroStream presents a special series of expert previews on major genitourinary oncology guidelines. In this issue, Professor Cuijian Zhang from Peking University First Hospital, Secretary of the CSCO Urothelial Carcinoma Expert Committee, discusses the evolution of the CSCO urothelial carcinoma guidelines, highlights potential updates in the upcoming edition, and shares insights into the clinical significance of emerging evidence and future directions in the field. His perspectives offer clinicians an early look at evolving treatment paradigms aimed at improving outcomes for Chinese patients.
Old Drug, New Use! Professor Kan Gong’s Team from Peking University First Hospital Collaborates with International Experts to Propose a Novel Combination Strategy for Renal Cell Carcinoma

Old Drug, New Use! Professor Kan Gong’s Team from Peking University First Hospital Collaborates with International Experts to Propose a Novel Combination Strategy for Renal Cell Carcinoma

Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, among which approximately 75% are clear cell renal cell carcinoma (ccRCC). Loss of the VHL gene is the key molecular event driving this disease. VHL inactivation places tumor cells in a persistent state of “pseudohypoxia,” continuously activating HIF-2α-centered oncogenic transcriptional programs that promote angiogenesis, cell proliferation, and metabolic reprogramming.
Chronicles of Genitourinary Oncology · 2026 | Led by Professor Jun Guo, Experts Highlight the Year’s Landmark Breakthroughs in Genitourinary Cancer Care (Part II)

Chronicles of Genitourinary Oncology · 2026 | Led by Professor Jun Guo, Experts Highlight the Year’s Landmark Breakthroughs in Genitourinary Cancer Care (Part II)

From the first glimmer of insight in 1941, when Professor Charles Huggins discovered the hormone dependence of prostate cancer, to today’s flourishing era of precision oncology, the field of genitourinary cancers has traveled an extraordinary path—from silence and therapeutic limitation to an age of precision-driven breakthroughs. As both a participant in and witness to this journey, I feel deeply honored and profoundly inspired.
The 4th Urologic Oncology Clinical Research Conference | Professor Jun Guo on the Innovation Momentum and Future Direction of Chinese Genitourinary Oncology Research

The 4th Urologic Oncology Clinical Research Conference | Professor Jun Guo on the Innovation Momentum and Future Direction of Chinese Genitourinary Oncology Research

The 4th Urologic Oncology Clinical Research Conference brought together leading experts, investigators, and innovators to review the latest progress in genitourinary oncology research in China. Alongside academic forums and international expert discussions, the meeting also released the 2025 Annual Report on Chinese Genitourinary Oncology Clinical Research, offering a comprehensive overview of the field’s recent development.